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W e read with great interest the timely and inform-ative editorial by Kaiser et al on managing cer-
tain endocrine conditions during COVID-19 pandemic 
(1). However, a couple of equally important areas of 
concern were not mentioned.
First, the management of hypoparathyroidism, par-
ticularly in light of recalled recombinant human para-
thyroid hormone, deserves some attention. Patients 
with symptomatic COVID-19 infection manifest sev-
eral electrolyte abnormalities, including serum calcium. 
Hypoparathyroid patients can be at risk of a sudden 
drop in serum calcium level after missing only a few 
doses of calcitriol and calcium, and may develop tetany, 
laryngeal spasm, and seizures. The only recourse during 
the COVID-19 pandemic is to administer intravenous 
calcium in an emergency room, which should be avoided 
during a pandemic for obvious reasons. In addition, 
clinicians should be aware of electrocardiogram abnor-
malities if patients are being treated with chloroquine, 
hydroxychloroquine, or azithromycin, all of which are 
known to cause prolonged corrected QT interval (2), 
as does acute and severe hypocalcemia (3). Thus, there 
is a need for close monitoring of serum calcium levels 
in symptomatic COVID patients, and adherence with 
calcitriol and calcium supplements as prescribed and 
sick-day guidelines (4).
A second area of concern during this pandemic is 
the potential for interruption of parenteral treatments 
in patients with osteoporosis, many of whom are in 
the high-risk group for COVID-19 infection because 
of advanced age and/or comorbidities. The spread of 
COVID-19 infection leading to limited or no access to 
clinics or infusion centers may result in missing sched-
uled time-sensitive parenteral medications. Although 
the administration of intravenous zoledronic acid can 
be delayed for a few months to a year, such time-lapse 
latitude does not apply to subcutaneous denosumab be-
cause of the potential for so-called “rebound fractures” 
(5), although there is no consensus on this complication 
(6). Nevertheless, it is important not to delay the sched-
uled denosumab dose by more than 4 to 6 weeks. Clinics 
could accommodate the visits for administration of in-
jectable medications by taking necessary precautions to 
ensure the health and safety of patients or temporarily 
switch treatment to an oral bisphosphonate. Another 
option is to self-administer denosumab if the patient is 
reluctant to come to the clinic. Amgen, the manufac-
turer of denosumab, may have resources available to 
help patients with self-administration. Also, because 
there is an increased risk of thromboembolic events re-
lated to COVID-19 infection (7), it is best to discontinue 
raloxifene, which is also associated with such risk (8).
Finally, timing the transition of treatment from 
anabolic (teriparatide, abaloparatide, romosozumab) 
to injectable antiresorptive therapy (zoledronic acid, 
denosumab) during a pandemic is also important. 
Admittedly, there are no guidelines or consensus on 
how best to achieve these transitions, but we recom-
mend continuing anabolic therapies for an additional 
1 to 2  months. If the transition must be made, the 
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interval between treatments should not exceed 2 to 4 
weeks because of concerns related to rapid and sub-
stantial decline in bone density. In patients on monthly 
romosozumab, the scheduled dose can be delayed for 
1 to 2  months. These potential approaches may vary 
among local practices depending on available resources 
and infrastructure.
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